MENU

KIR3DL2-directed CAR T-cells: Preclinical efficacy for TCLs

bioRxiv USA
Overview
Researchers have developed a novel CAR T-cell therapy targeting KIR3DL2 (CD158k) to treat cutaneous and systemic T-cell lymphomas (TCLs). The therapy demonstrated sustained tumor regression in xenograft models with minimal off-target activity, providing a potential alternative to pan-T-cell-directed strategies.
In Depth

Key Findings

The study establishes the preclinical efficacy and safety of 3DL2CART cells in treating various subtypes of cutaneous and systemic T-cell lymphomas. In vivo testing showed sustained tumor regression and prolonged survival across two cell line-derived xenograft models of cutaneous TCL and one patient-derived xenograft model of hepatosplenic TCL. The therapy exhibited minimal off-target activity against bystander immune cells and no appreciable fratricide.

Technical Details

The researchers identified KIR3DL2 (CD158k) as a viable target using single-cell RNA-seq data analysis and flow cytometric phenotyping. Findings indicated that KIR3DL2 expression is restricted to a subset of mature NK cells and a minor fraction of CD8⁺ T cells, with negligible expression in other healthy adult tissues. Anti-KIR3DL2 CAR constructs (3DL2CARs) selectively redirected T cells against antigen-positive cell lines, triggering antigen-specific signaling, cytotoxicity, proliferation, and cytokine production.

To address the risk of tumor cell contamination in autologous CAR T-cell products, a two-tiered safety strategy was implemented:

  • Immunomagnetic depletion of KIR3DL2-positive tumor cells.
  • In vivo activation of a safety switch to prevent immune escape if malignant cells are inadvertently transduced.

Background & Context

While CAR T-cell therapy has transformed the treatment of multiple myeloma and B-cell malignancies, its application to T-cell lymphomas has been limited by a lack of safe target antigens. Targeting pan-T antigens is possible but carries a substantial risk of infection and immunosuppression.

Significance & Outlook

By targeting KIR3DL2, this approach offers a more precise alternative to pan-T-cell-directed strategies. The results support the clinical translation of 3DL2CART-cell therapy to address the critical unmet clinical need for patients with relapsed/refractory cutaneous and systemic TCLs.

Source: https://doi.org/10.64898/2026.11.05.764385

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC